A single dose of psilocybin induces lasting changes in metabolic connectivity within biologically informed rat brain networks related to compulsions and anxiety.
Frederik Gudmundsen,
No information about this author
Julia Czurylo,
No information about this author
Camilla Trang Vo
No information about this author
et al.
Published: May 28, 2024
Serotonergic
psychedelic
drugs
have
shown
promising
benefits
in
trials
for
various
neuropsychiatric
disorders.
While
the
acute
effects
of
these
psychedelics
last
only
a
few
hours,
positive
therapeutic
can
persist
long
after
single
administration.
produce
their
by
activating
serotonin
2A
receptors,
but
they
differ
other
pharmacological
aspects.
To
guide
safest
and
most
effective
treatment
specific
disorders,
it
is
crucial
to
gain
better
understanding
distinct
long-term
on
living
brain.
Here
we
demonstrate
how
three
different
serotonergic
psychedelics;
psilocybin,
LSD
2C-B,
induce
patterns
rat
brain
metabolic
activity
connectivity.
The
doses
administered
were
chosen
reflect
humans.
We
found
that,
psilocybin
induced
pattern
effects,
particularly
focusing
changes
connectivity
between
cortical
regions
such
as
orbitofrontal,
medial
prefrontal,
insula
cortex,
well
with
dorsal
striatum,
thalamus,
hippocampus.
In
contrast,
2C-B
showed
more
similar
impacts
centered
inhibition
anterior
cingulate
cortex.
This
was
accompanied
increased
amygdala
hypothalamus,
along
heightened
dopamine
cell-rich
ventral
tegmental
area
substantia
nigra.
Our
findings
within
networks
provide
new
insights
into
shared
drug-selective
mechanisms
underlying
substances
These
could
offer
guidance
which
might
be
beneficial
certain
psychiatric
diseases.
Language: Английский
Licit use of illicit drugs for treating depression: the pill and the process
Journal of Clinical Investigation,
Journal Year:
2024,
Volume and Issue:
134(12)
Published: June 16, 2024
Psilocybin,
MDMA,
and
ketamine
have
emerged
as
potentially
effective
treatments
for
rapid
amelioration
of
the
symptoms
mood
related
psychiatric
disorders.
All
clinical
data
collected
so
far
with
regard
to
psilocybin
or
which
reported
positive
outcomes
treating
depression,
anxiety,
posttraumatic
stress
disorder,
drug
alcohol
use
disorders,
involved
clinician-assisted
intervention.
While
case
is
assumed
be
different,
first
report
successful
in
psychiatry
depression
was
combination
psychotherapy,
an
emerging
literature
suggests
that
subjective
state
individual
experiences
predicts
outcome.
This
Review
will
focus
on
(a)
a
brief
review
literature,
showing
context
process
administration
has
been
integrative
component
published
work;
(b)
importance
trials
compare
efficacy
("pill")
stand-alone
treatment
versus
psychological
support
("process");
(c)
suggestions
future
approaches
animal
models
take
into
account
role
systems
behavioral
neuroscience
explaining
potential
context,
experience,
expectancy
effect.
Language: Английский